Table 1 Comparison of baseline data
Indicators | PFA group (n = 36) | Radiofrequency ablation group (n = 36) | F value | P value |
|---|---|---|---|---|
Male [n (%)] | 26 (72.2) | 23 (63.9) | – | 1.000 |
Age (year) | 68.36 ± 15.07 | 64.64 ± 14.43 | 0.560 | 0.560 |
Weight (kg) | 60.91 ± 9.08 | 67.55 ± 9.42 | − 1.682 | 0.108 |
Left atrial inner diameter (mm) | 34.91 ± 7.60 | 33.64 ± 9.51 | 0.347 | 0.732 |
Left ventricular ejection fraction (%) | 59.27 ± 11.05 | 59.18 ± 8.96 | 0.210 | 0.983 |
CHS2DS2-VASc score (points) | 2.82 ± 1.83 | 2.73 ± 1.95 | 0.113 | 0.912 |
HAS-BLED score (points) | 2.42 ± 2.02 | 2.00 ± 1.61 | 0.584 | 0.566 |
Paroxysmal atrial fibrillation [n (%)] | 21(58.3) | 19 (52.8) | – | 1.000 |
Hypertension [n (%)] | 19 (52.8) | 16 (44.4) | 0.001 | 1.000 |
Diabetes [n (%)] | 0 (0.0) | 3(8.3) | – | 0.476 |
Coronary heart disease [n (%)] | 10 (27.8) | 6 (16.7) | – | 1.000 |
Previous stroke [n (%)] | 10 (27.8) | 7 (19.4) | – | 1.000 |
NOAC [n (%)] | 36 (100.0) | 36 (100.0) | – | – |
Class I antiarrhythmic drugs [n (%)] | 0 (0.0) | 2(5.6) | – | 1.000 |
Class II antiarrhythmic drugs [n (%)] | 23 (63.9) | 24 (66.7) | – | 1.000 |
Class III antiarrhythmic drugs [n (%)] | 13 (36.1) | 7 (19.4) | – | 0.635 |